Hospital
The Pennsylvania Hospital of the University of Pennsylvania Health Sys
The Pennsylvania Hospital of the University of Pennsylvania Health Sys was paid $25.68M by Medicaid between Aug 2018 and Dec 2024, across 297 billing codes. Its largest line is G0378, Hospital observation service, per hour — 27% of everything it billed.
33Billing provider infoTHE PENNSYLVANIA HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA HEALTH SYS
PHILA, PA 19107
PHILA, PA 19107
33aNPI1063489342assigned 03/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$25.68M
24GClaims413,275
24DCodes billed297
24AFirst – last monthAug 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#11 of 154
Median peer was paid$2.82M
This provider vs. median9.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 96 | $95.70 | |
| 2019 | 1,946 | $29K | |
| 2020 | 54,808 | $2.65M | |
| 2021 | 151,312 | $9.16M | |
| 2022 | 59,687 | $5.04M | |
| 2023 | 62,550 | $4.36M | |
| 2024incomplete | 82,876 | $4.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0378 | Hospital observation service, per hour | 27% | 6,367 | 5,287 | $6.95M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 24,621 | 22,863 | $4.96M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 18,396 | 17,254 | $3.66M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 17,360 | 16,214 | $3.48M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.3% | 7,533 | 7,095 | $597K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.6% | 3,123 | 3,076 | $403K |
| 64483 | 1.3% | 278 | 272 | $341K | |
| 99235 | <1% | 248 | 196 | $251K | |
| 57420 | <1% | 178 | 168 | $198K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,334 | 3,135 | $183K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,365 | 1,297 | $179K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,066 | 726 | $154K |
285 more codes
| 64493 | <1% | 158 | $148K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,184 | $141K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,599 | $141K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,252 | $128K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 316 | $125K |
| 59025 | Fetal non-stress test | <1% | 5,431 | $116K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 29,129 | $105K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 659 | $103K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,394 | $102K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,382 | $102K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,241 | $100K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,732 | $99K |
| 20610 | <1% | 299 | $95K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,222 | $92K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,085 | $89K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 529 | $89K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 884 | $85K |
| 36415 | Collection of venous blood by venipuncture | <1% | 34,625 | $71K |
| 73562 | <1% | 3,457 | $69K | |
| 76801 | <1% | 1,348 | $68K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,111 | $65K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,216 | $65K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 332 | $64K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 197 | $63K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 246 | $63K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 719 | $62K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,019 | $60K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,177 | $58K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,404 | $56K |
| 80053 | Comprehensive metabolic panel | <1% | 7,957 | $54K |
| 76818 | <1% | 560 | $49K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,097 | $49K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,068 | $42K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 614 | $42K |
| 72110 | <1% | 1,361 | $41K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,913 | $39K |
| 76642 | <1% | 665 | $37K | |
| 77066 | Tomosynthesis, mammo | <1% | 322 | $35K |
| 76820 | <1% | 936 | $35K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 34 | $34K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,248 | $33K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,233 | $31K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,481 | $30K |
| 73221 | <1% | 101 | $30K | |
| 73564 | <1% | 1,138 | $29K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 306 | $28K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,421 | $26K |
| 72141 | <1% | 107 | $25K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,058 | $25K |
| 82728 | <1% | 2,634 | $25K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 82 | $25K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 991 | $24K |
| 73030 | <1% | 1,340 | $24K | |
| 74183 | <1% | 60 | $24K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 300 | $24K |
| 71250 | <1% | 326 | $23K | |
| 80076 | <1% | 5,778 | $22K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $21K |
| 96376 | <1% | 693 | $21K | |
| 96417 | <1% | 239 | $20K | |
| 76536 | <1% | 316 | $19K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 225 | $18K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 998 | $18K |
| 73502 | <1% | 722 | $16K | |
| 77065 | Tomosynthesis, mammo | <1% | 211 | $16K |
| 72197 | <1% | 24 | $16K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,589 | $15K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 310 | $14K |
| 73130 | <1% | 846 | $14K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,023 | $14K |
| 96415 | <1% | 245 | $14K | |
| 76770 | <1% | 281 | $14K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 872 | $14K |
| 85027 | <1% | 3,071 | $13K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 685 | $12K |
| 70486 | <1% | 139 | $12K | |
| 73560 | <1% | 592 | $12K | |
| 84484 | <1% | 2,540 | $12K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 59 | $11K |
| 72100 | <1% | 495 | $11K | |
| 93971 | <1% | 297 | $11K | |
| 84466 | <1% | 1,139 | $10K | |
| 73110 | <1% | 623 | $10K | |
| 84702 | <1% | 1,642 | $10K | |
| 93975 | <1% | 139 | $10K | |
| 81025 | <1% | 5,208 | $10K | |
| 95886 | <1% | 221 | $9K | |
| 73630 | <1% | 610 | $9K | |
| 73521 | <1% | 284 | $9K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 747 | $9K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,727 | $8K |
| 77062 | <1% | 302 | $8K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 494 | $8K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 463 | $8K |
| 73610 | <1% | 380 | $8K | |
| 80061 | Lipid panel | <1% | 795 | $7K |
| 77336 | <1% | 173 | $7K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 44 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 283 | $7K |
| 83735 | <1% | 3,029 | $7K | |
| 97803 | <1% | 63 | $7K | |
| 83540 | <1% | 1,225 | $7K | |
| 80354 | <1% | 296 | $7K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,781 | $7K |
| 86900 | <1% | 1,480 | $7K | |
| 83880 | <1% | 560 | $6K | |
| 36591 | <1% | 150 | $6K | |
| 19083 | <1% | 13 | $6K | |
| 94726 | <1% | 149 | $6K | |
| 94729 | <1% | 151 | $6K | |
| 83690 | <1% | 2,922 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 229 | $6K |
| 86850 | <1% | 1,263 | $6K | |
| 85730 | <1% | 1,836 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,467 | $5K |
| 87631 | <1% | 79 | $5K | |
| OP250 | <1% | 1,507 | $5K | |
| 72040 | <1% | 237 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,017 | $5K |
| 85610 | <1% | 2,297 | $5K | |
| 72050 | <1% | 140 | $5K | |
| 82803 | <1% | 554 | $5K | |
| 70491 | <1% | 41 | $4K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 106 | $4K |
| 73080 | <1% | 241 | $4K | |
| 72070 | <1% | 146 | $4K | |
| Q3014 | Telehealth originating site facility fee | <1% | 881 | $4K |
| X0621 | <1% | 22 | $4K | |
| 83605 | <1% | 1,181 | $3K | |
| 82607 | <1% | 513 | $3K | |
| 81003 | <1% | 2,738 | $3K | |
| 88342 | <1% | 72 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 820 | $3K |
| 52000 | <1% | 14 | $3K | |
| 86803 | <1% | 185 | $3K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 43 | $3K |
| 86901 | <1% | 1,264 | $3K | |
| 74246 | <1% | 37 | $3K | |
| 77061 | <1% | 118 | $3K | |
| 80320 | <1% | 478 | $3K | |
| 93798 | <1% | 71 | $3K | |
| 81002 | <1% | 1,592 | $3K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 31 | $3K |
| 73140 | <1% | 158 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 66 | $2K |
| 85007 | <1% | 1,191 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 703 | $2K |
| 73700 | <1% | 31 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 61 | $2K |
| 82962 | <1% | 2,834 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 502 | $2K |
| 81001 | <1% | 1,567 | $2K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 3,117 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,533 | $2K |
| 96367 | <1% | 99 | $2K | |
| 85379 | <1% | 351 | $2K | |
| 72052 | <1% | 38 | $2K | |
| 88360 | <1% | 45 | $2K | |
| 82746 | <1% | 263 | $2K | |
| 93970 | <1% | 26 | $2K | |
| 82247 | <1% | 247 | $2K | |
| 95806 | <1% | 233 | $1K | |
| C1769 | Guide wire | <1% | 108 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,960 | $1K |
| 86592 | <1% | 570 | $1K | |
| 84100 | <1% | 808 | $1K | |
| 82330 | <1% | 502 | $1K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 18 | $1K |
| 82570 | <1% | 331 | $1K | |
| 87186 | <1% | 335 | $1K | |
| 86480 | <1% | 26 | $1K | |
| 96411 | <1% | 14 | $860.93 | |
| 85045 | <1% | 407 | $813.59 | |
| 82784 | <1% | 30 | $805.88 | |
| 83615 | <1% | 189 | $782.08 | |
| 85652 | <1% | 427 | $773.03 | |
| 85384 | <1% | 176 | $764.50 | |
| 93922 | <1% | 25 | $760.71 | |
| 87340 | <1% | 69 | $760.62 | |
| J3490 | Unclassified drugs | <1% | 3,580 | $652.52 |
| 87077 | <1% | 194 | $627.51 | |
| 94010 | <1% | 40 | $599.16 | |
| 82550 | <1% | 183 | $541.17 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 42 | $536.50 |
| 80050 | General health panel | <1% | 18 | $515.03 |
| 76000 | <1% | 173 | $510.61 | |
| 87070 | <1% | 167 | $497.04 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,261 | $493.34 |
| 94761 | <1% | 195 | $490.08 | |
| 95909 | <1% | 12 | $488.40 | |
| 59899 | <1% | 17 | $451.44 | |
| 77300 | <1% | 14 | $443.68 | |
| 84153 | <1% | 30 | $435.62 | |
| 73590 | <1% | 33 | $420.53 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,658 | $376.50 |
| 81015 | <1% | 216 | $364.62 | |
| 87205 | <1% | 185 | $361.03 | |
| 80179 | <1% | 46 | $360.11 | |
| 86140 | <1% | 160 | $351.26 | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,216 | $337.95 |
| 84550 | <1% | 100 | $328.61 | |
| 84156 | <1% | 161 | $324.11 | |
| 84134 | <1% | 28 | $307.63 | |
| 87040 | <1% | 97 | $306.32 | |
| 84132 | <1% | 526 | $304.14 | |
| 88112 | <1% | 14 | $299.39 | |
| 72114 | <1% | 12 | $295.18 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 578 | $290.15 |
| 84295 | <1% | 436 | $273.73 | |
| 82043 | <1% | 51 | $271.13 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 23 | $269.71 |
| 82378 | <1% | 31 | $251.11 | |
| 80143 | <1% | 34 | $250.44 | |
| 86141 | <1% | 87 | $243.64 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,517 | $241.66 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 690 | $222.36 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,658 | $215.93 |
| 51798 | <1% | 66 | $213.68 | |
| 82565 | <1% | 43 | $170.73 | |
| 85018 | <1% | 440 | $168.93 | |
| 80329 | <1% | 28 | $167.97 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 45 | $160.68 |
| 93017 | <1% | 13 | $152.83 | |
| 73552 | <1% | 13 | $146.07 | |
| 82947 | <1% | 278 | $135.72 | |
| 87088 | <1% | 20 | $133.75 | |
| 90715 | <1% | 42 | $131.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,463 | $125.77 |
| 36000 | <1% | 557 | $124.58 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 793 | $123.62 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 632 | $97.03 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 27 | $87.08 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,393 | $86.17 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 102 | $85.20 |
| 86706 | <1% | 12 | $83.35 | |
| 89051 | <1% | 15 | $80.71 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 204 | $77.00 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 689 | $76.55 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,833 | $75.79 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,656 | $74.97 |
| 87081 | <1% | 38 | $72.91 | |
| 84439 | <1% | 13 | $72.23 | |
| 85008 | <1% | 115 | $67.04 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 588 | $66.84 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 99 | $50.90 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 81 | $42.64 |
| 82010 | <1% | 26 | $28.67 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 17 | $26.41 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 943 | $22.48 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,895 | $19.41 |
| 88341 | <1% | 32 | $16.50 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 16 | $16.20 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 350 | $13.92 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 740 | $10.73 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 278 | $9.44 |
| C2627 | Catheter, suprapubic/cystoscopic | <1% | 12 | $7.62 |
| 99201 | <1% | 51 | $5.45 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 981 | $3.97 |
| J1815 | Injection, insulin, per 5 units | <1% | 520 | $3.85 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,426 | $3.12 |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,268 | $0.68 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 805 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 208 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 64 | $0.00 |
| J9271 | Injection, pembrolizumab, 1 mg | 0% | 25 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 134 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 747 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 426 | $0.00 |
| 87210 | 0% | 27 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 59 | $0.00 |
| J1750 | Injection, iron dextran, 50 mg | 0% | 18 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 13 | $0.00 |
| S5000 | Prescription drug, generic | 0% | 28 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 14 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 470 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 281 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 78 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 15 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 41 | $0.00 |
| 64494 | 0% | 13 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 169 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 40 | $0.00 |
| 88304 | 0% | 12 | $0.00 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 31 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCORMICK, THOMAS (AVP FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Trustees of the University of Pennsylvania | Philadelphia, PA | $84.02M |
| Presbyterian Medical Center of the University of Pennsylvania Health S | Philadelphia, PA | $23.27M |
| Hall-Mercer Cmh-Mrc of Pennsylvania Hosp | Philadelphia, PA | $14.08M |
| Hall-Mercer Cmh-Mrc of PA Hosp | Phila, PA | $6.82M |
| Hospital of University of Pennsylvania | Phila, PA | $2.61M |
| Penn Presbyterian Medical CTR Detox Rehab | Phila, PA | $1.60M |
| Penn Presybyterian Medical Center | Phila, PA | $1.48M |
| The Pennsylvania Hospital of the University of Pennsylvania Health Sys | Philadelphia, PA | $69K |
| Thomas E Mccormick, MD, PC | Rutland, VT | $22K |
| Presbyterian Medical Center of the University of Pennsylvania Health S | Philadelphia, PA | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.